P L Olliaro

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. ncbi request reprint Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review
    P L Olliaro
    UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, CH 1211 Geneva 27, Switzerland
    J Postgrad Med 50:40-4. 2004
  2. doi request reprint Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999-2009
    Julien Zwang
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Malar J 13:114. 2014
  3. doi request reprint Practical dosing of praziquantel for schistosomiasis in preschool-aged children
    Piero L Olliaro
    UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Trop Med Int Health 18:1085-9. 2013
  4. pmc A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project
    Corinne S C Merle
    Faculty of Epidemiology and Population Health, Tropical Epidemiological Group, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Trials 13:61. 2012
  5. pmc Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
    Eva Maria Staehli Hodel
    Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland
    Malar J 12:235. 2013
  6. pmc Pharmaceutical development and optimization of azithromycin suppository for paediatric use
    Tina Kauss
    Univ Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France
    Int J Pharm 441:218-26. 2013
  7. pmc Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis
    Piero Olliaro
    UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases WHO TDR, Geneva, Switzerland
    PLoS Negl Trop Dis 7:e2130. 2013
  8. pmc Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western Senegal
    Philippe Brasseur
    Institut de recherche pour le developpement IRD, UMR 198, 1386BP, Dakar, Senegal
    Malar J 11:402. 2012
  9. pmc Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa
    Julien Zwang
    Drugs for Neglected Diseases Initiative DNDi, Geneva, Switzerland
    Malar J 11:260. 2012
  10. pmc Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa
    Julien Zwang
    Drugs for Neglected Diseases Initiative DNDi, Geneva, Switzerland
    Malar J 11:25. 2012

Collaborators

Detail Information

Publications51

  1. ncbi request reprint Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review
    P L Olliaro
    UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, CH 1211 Geneva 27, Switzerland
    J Postgrad Med 50:40-4. 2004
    ..This review will summarise current antimalarial drug developments and outline recent clinical research that aims to bring artemisinin based combinations to those that need them most...
  2. doi request reprint Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999-2009
    Julien Zwang
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Malar J 13:114. 2014
    ..This makes it all too important to measure the dynamics of parasite clearance in African patients treated with ACT over time, to understand trends and detect changes early enough to intervene..
  3. doi request reprint Practical dosing of praziquantel for schistosomiasis in preschool-aged children
    Piero L Olliaro
    UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Trop Med Int Health 18:1085-9. 2013
    ..Current 600-mg tablets are differently scored to give units of 150 mg (a quarter of a tablet) or 300 mg (half a tablet)...
  4. pmc A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project
    Corinne S C Merle
    Faculty of Epidemiology and Population Health, Tropical Epidemiological Group, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Trials 13:61. 2012
    ..re-infections in the definition of the outcome? What is the optimal length of patient follow-up? Is blinding appropriate when treatment duration in test arm is shorter? What are the appropriate assumptions for sample size calculation?..
  5. pmc Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
    Eva Maria Staehli Hodel
    Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland
    Malar J 12:235. 2013
    ..This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability...
  6. pmc Pharmaceutical development and optimization of azithromycin suppository for paediatric use
    Tina Kauss
    Univ Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France
    Int J Pharm 441:218-26. 2013
    ..This product has potential both as a classical antibiotic and as a product for use in severely ill children in rural areas. Industrial partners for further development are being sought...
  7. pmc Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis
    Piero Olliaro
    UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases WHO TDR, Geneva, Switzerland
    PLoS Negl Trop Dis 7:e2130. 2013
    ..The limited resources available for CL have to be concentrated in clinical studies of excellence that meet international quality standards...
  8. pmc Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western Senegal
    Philippe Brasseur
    Institut de recherche pour le developpement IRD, UMR 198, 1386BP, Dakar, Senegal
    Malar J 11:402. 2012
    ..Cohort event monitoring (CEM) is a WHO (World Health Organization)-recommended practice; testing its performance and feasibility in routine practice in malaria-endemic is important...
  9. pmc Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa
    Julien Zwang
    Drugs for Neglected Diseases Initiative DNDi, Geneva, Switzerland
    Malar J 11:260. 2012
    ..The widespread use of artesunate-amodiaquine (ASAQ) for treating uncomplicated malaria makes it important to gather and analyse information on its tolerability...
  10. pmc Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa
    Julien Zwang
    Drugs for Neglected Diseases Initiative DNDi, Geneva, Switzerland
    Malar J 11:25. 2012
    ..A comprehensive appreciation of its effects on haematology vs other anti-malarials is needed in view of potential safety liabilities...
  11. pmc Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial
    Dorothee Heemskerk
    Hospital for Tropical Diseases Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme 190 Ben Ham Tu, District 5, Ho Chi Minh City, Vietnam
    Trials 12:25. 2011
    ....
  12. pmc Changing patterns of malaria during 1996-2010 in an area of moderate transmission in southern Senegal
    Philippe Brasseur
    Institut de recherche pour le developpement IRD, UMR 198, Rue Wagane Diouf Georges Pompidou, Dakar, Senegal
    Malar J 10:203. 2011
    ..Since 2000, there has been a staggered deployment of artesunate-amodiaquine after parasitological confirmation; this was adopted nationally in 2006...
  13. pmc The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership
    Catherine Lacaze
    Ellipse Pharmaceuticals, Pessac, France
    Malar J 10:142. 2011
    ....
  14. pmc Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa
    Felista Mwingira
    Dares Salaam University College of Education P O BOX 2329, Dar es Salaam, Tanzania
    Malar J 10:79. 2011
    ..This study presents the genetic diversity of P. falciparum msp1, msp2 and glurp markers in selected sub-Saharan Africa countries with varying levels of endemicity namely Malawi, Tanzania, Uganda, Burkina Faso and São Tomé...
  15. pmc The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria
    Sue J Lee
    Mahidol Oxford Tropical Medicine Research Unit MORU, Mahidol University, Faculty of Tropical Medicine, 3rd Floor, 60th Anniversary Chalermprakiat Building, 420 6 Ratchawithi Rd, Ratchathewi District, Bangkok 10400, Thailand
    Malar J 7:149. 2008
    ..Anaemia is assessed either by measurement of the haematocrit or the haemoglobin concentration. For comparisons across studies, it is often necessary to derive one measure from the other...
  16. pmc World Antimalarial Resistance Network (WARN) IV: clinical pharmacology
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Malar J 6:122. 2007
    ....
  17. pmc The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum
    Sodiomon B Sirima
    Centre National de Recherche et de Formation sur le Paludisme CNRFP, BP 2208, Ouagadougou, Burkina Faso
    Malar J 8:48. 2009
    ..Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) recommended by the WHO for treating Plasmodium falciparum malaria. Fixed-dose AS/AQ is new, but its safety and efficacy are hitherto untested...
  18. pmc Ensuring sustained ACT production and reliable artemisinin supply
    Jean Marie Kindermans
    AEDES Foundation, 34, rue Joseph II, 1000, Brussels, Belgium
    Malar J 6:125. 2007
    ..Production and cost data provided in this paper are based on an ongoing project (Artepal). Stability data are derived from a development project on rectal artesunate...
  19. pmc World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs
    Ric N Price
    International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
    Malar J 6:119. 2007
    ..This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed...
  20. pmc Geometric least squares means ratios for the analysis of Plasmodium falciparum in vitro susceptibility to antimalarial drugs
    Michel Vaillant
    Clinical Epidemiology and Public Health Unit, Centre for Health Studies, Centre de Recherche Publique CRP Santé, Luxembourg
    Malar J 6:156. 2007
    ..For antimalarial drugs, as well as for antibiotics, assessing changes in microbe susceptibility over time under drug pressure would help inform treatment policy decisions, but no standard statistical method exists as yet...
  21. pmc Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis
    Julien Zwang
    Shoklo Malaria Research Unit, Mae Sot, Thailand
    Malar J 8:203. 2009
    ..It was necessary to evaluate the efficacy of ACT, recently adopted by the World Health Organization (WHO) and deployed over 80 countries, in order to make an evidence-based drug policy...
  22. pmc Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia
    Lyda Osorio
    Internacional Centre for Medical Research and Training CIDEIM Avenida 1N 3 03, Cali, Colombia
    Malar J 6:25. 2007
    ..Artemisinin-based combination therapy (ACT) is being widely promoted as a strategy to counteract the increase in Plasmodium falciparum antimalarial drug resistance...
  23. pmc Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children
    Elizabeth A Ashley
    Epicentre, Paris, France
    Malar J 7:154. 2008
    ..Use of different methods for assessing the efficacy of artemisinin-based combination antimalarial treatments (ACTs) will result in different estimates being reported, with implications for changes in treatment policy...
  24. pmc A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria
    Stephane Picot
    Malaria Research Unit, EA 4170, University Lyon 1, Faculty of Medicine, Lyon, France
    Malar J 8:89. 2009
    ..The purpose of this systematic review was to determine the risk of treatment failure associated with specific polymorphisms in the parasite genome or gene copy number...
  25. pmc Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs)
    Jean Marie Kindermans
    AEDES Foundation, Brussels, Belgium
    Malar J 6:91. 2007
    ..There is no ideal method to quantify drug requirements for malaria. Morbidity data give uncertain estimations. This study uses drug consumption to provide elements to help estimate quantities and financial requirements of ACTs...
  26. pmc Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal
    Philippe Brasseur
    UR 077, IRD, Dakar, Senegal
    Malar J 6:150. 2007
    ..There are no data on the long term use of an artemisinin combination treatment in moderate or high transmission areas of Africa...
  27. pmc Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers
    Visweswaran Navaratnam
    National Center for Drug Research CRD, Universiti Sains Malaysia USM, 11800 Minden, Pulau Pinang, Penang, Malaysia
    Eur J Clin Pharmacol 65:809-21. 2009
    ..This study examines the bioavailability and tolerability of a fixed (200 mg artesunate + 540 mg amodiaquine) and loose (200 mg + 612 mg) combination with a 2x2 cross-over design in 24 healthy volunteers...
  28. doi request reprint Editorial commentary: mortality associated with severe Plasmodium falciparum malaria increases with age
    Piero Olliaro
    United Nations Children s Fund United Nations Development Programme World Bank World Health Organization Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 47:158-60. 2008
  29. ncbi request reprint Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004
    Piero L Olliaro
    UNICEF UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases, WHO, Geneva, Switzerland
    Lancet Infect Dis 5:763-74. 2005
    ..India, Bangladesh, and Nepal agreed recently to undertake measures towards the elimination of visceral leishmaniasis. The lessons learnt in Bihar could help inform policy decisions both regionally and elsewhere...
  30. ncbi request reprint Drug resistance hampers our capacity to roll back malaria
    Piero Olliaro
    United Nations International Children s Emergency Fund United Nations Development Programme World Bank World Health Organization Special Programme on Research and Training in Tropical Diseases, Geneva, Switzerland
    Clin Infect Dis 41:S247-57. 2005
    ..The current situation favors the development of sensible strategies to restrain resistance...
  31. pmc Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa
    Piero Olliaro
    United Nations Children s Fund United Nations Development Program World Bank World Health Organization Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Am J Trop Med Hyg 85:619-25. 2011
    ..These analyses provides information on hematologic variations caused by malaria...
  32. ncbi request reprint Antimalarial compounds: from bench to bedside
    Piero L Olliaro
    UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    J Exp Biol 206:3753-9. 2003
    ..This review will summarise current antimalarial drug developments and outline recent clinical research that aims to bring artemisinin-based combinations to those that need them most...
  33. pmc Pharmacokinetics of artesunate after single oral administration to rats
    P L Olliaro
    UNPD World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, CDS, World Health Organization, 20, avenue AppiaCH 1211 Geneva 27, Switzerland
    BMC Pharmacol 1:12. 2001
    ..In order to study the absorption phase of the kinetics of artesunate following oral administration in rats, samples were collected at baseline, and then 0.5, 2, 5, 10, 15, 30, 45, 60 and 120 minutes after a single dose of 150 mg...
  34. ncbi request reprint Controlling malaria: challenges and solutions
    P Olliaro
    UNDP World Bank World Health Organization Special Program for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Trop Med Int Health 6:922-7. 2001
    ..The paper describes a multilateral, multidisciplinary research project on artemisinin-based combination therapy, which offers a new and potentially highly effective way to prevent or retard the development of drug resistance...
  35. doi request reprint Standardised versus actual white cell counts in estimating thick film parasitaemia in African children under five
    Piero Olliaro
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Trop Med Int Health 16:551-4. 2011
    ....
  36. doi request reprint Drug combinations for visceral leishmaniasis
    Piero L Olliaro
    UNICEF UNPD World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Curr Opin Infect Dis 23:595-602. 2010
    ..Several attempts have been made to combine drugs for treating visceral leishmaniasis, but only recently have effective drugs become available and combinations been tested systematically...
  37. doi request reprint Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India
    P Olliaro
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Trop Med Int Health 14:88-92. 2009
    ..To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India...
  38. pmc Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal
    Piero L Olliaro
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases TDR, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Malar J 7:234. 2008
    ..Indicators of implementation and effects of IPTp-SP were collected in a rural clinic in Southern Senegal...
  39. ncbi request reprint [Treatment of malaria: outlook]
    Piero Olliaro
    Bull Acad Natl Med 191:1285-92. 2007
    ..The development and deployment of new products is both lengthy and complex...
  40. doi request reprint The global portfolio of new antimalarial medicines under development
    P Olliaro
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Clin Pharmacol Ther 85:584-95. 2009
    ..The portfolio is discussed in terms of the novelty of the new molecules and their potential health impact in terms of addressing the requirements for the control and eventual eradication of malaria...
  41. doi request reprint Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment
    Piero Olliaro
    UNICEF UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    Trop Med Int Health 13:83-90. 2008
    ..Current guidelines recommend treatment only when patients develop symptoms or at the end of follow-up. We wanted to assess prospectively the probability of becoming symptomatic and the risks of this practice...
  42. doi request reprint Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India
    Piero Olliaro
    UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Trop Med Int Health 14:918-25. 2009
    ..To assess the cost-effectiveness of current monotherapies and prospective combinations for treating visceral leishmaniasis (VL) in Bihar, India in terms of years of life lost (YLL) averted as well as deaths averted...
  43. ncbi request reprint Possible modes of action of the artemisinin-type compounds
    P L Olliaro
    UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases, CDS Cluster, 20, Avenue Appia, CH 1211, Geneva, Switzerland
    Trends Parasitol 17:122-6. 2001
    ..However, uncertainties remain as to how they act on the parasite and cause toxicity. In this review, we summarize current ideas...
  44. ncbi request reprint What role can public health institutions play in drug development for the poor? A case study of artesunate
    M Gomes
    Special Programme for Research and Training in Tropical Diseases, TDR WHO, Geneva, Switzerland
    Med Trop (Mars) 58:97-100. 1998
    ..In essence, each and every player has rallied in the challenge to reduce the discrepancy between need and availability of a drug that can has the potential to reduce mortality form the disease...
  45. ncbi request reprint Mode of action and mechanisms of resistance for antimalarial drugs
    P Olliaro
    World Health Organization, Communicable Diseases Cluster CDS, UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, CH 1211 27, Geneva, Switzerland
    Pharmacol Ther 89:207-19. 2001
    ..The use of closely related compounds has promoted the spread of multidrug resistant parasites. This review intends to collate contemporary knowledge, and also to highlight conflicting views on unresolved issues...
  46. pmc Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial
    M F Gomes
    UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
    Lancet 373:557-66. 2009
    ..We investigated whether this intervention reduced mortality and permanent disability...
  47. pmc Status of antimalarial drugs under development
    P L Olliaro
    Steering Committee on Drugs for Malaria, UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 73:565-71. 1995
    ..Some of these drugs may become available in the next few years. It is therefore essential to find mechanisms to ensure that they are made available at an affordable price to the populations that really need them...
  48. pmc Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria
    Walter R J Taylor
    Special Programme for Research and Training in Tropical Diseases, United Nations Children s Fund World Bank United Nations Development Programme World Health Organization, Geneva, Switzerland
    Bull World Health Organ 84:956-64. 2006
    ..To test a novel methodology to define age-based dosing regimens for the treatment of malaria with a new, user-friendly, blister-packaged fixed-dose combination of artesunate and amodiaquine...
  49. ncbi request reprint Drug resistant falciparum malaria and the use of artesunate-based combinations: focus on clinical trials sponsored by TDR
    Walter R Taylor
    UNDP World Bank World Health Organization Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
    J Vector Borne Dis 40:65-72. 2003
    ..They were high for amodiaquine-artesunate, variable for sulfadoxine/pyrimethamine-artesunate, and poor for chloroquine-artesunate...
  50. ncbi request reprint Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment
    Kefas Mugittu
    Ifakara Health Research and Development Centre, Ifakara, Tanzania
    Trop Med Int Health 12:219-23. 2007
    ..2%)] and 14 [24/51 (47.1%)]. These results impact significantly on resistance monitoring and point to the value of genotyping all recurrent infections in antimalarial trials...
  51. ncbi request reprint Miltefosine in visceral leishmaniasis
    Piero L Olliaro
    Lancet Infect Dis 3:70. 2003